Work

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone Induction and Consolidation with Tandem Transplant in High-Risk Newly Diagnosed Myeloma Patients: Final Results of the Phase 2 Study IFM 2018-04

Year: 2023

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2023-174044

Authors: Cyrille Touzeau, Aurore Perrot, Cyrille Hulin, Salomon Manier, Margaret Macro, Marie-Lorraine Chretien, Lionel Karlin, Olivier Decaux, Caroline Jacquet, Mourad Tiab, Xavier Leleu, Jill Corre, Alexandra Jobert, Lucie Planche, Herve Avet-Loiseau, Philippe Moreau

Institutions: Centre Hospitalier Universitaire de Nantes, Centre de Recherches en Cancérologie de Toulouse, Centre Hospitalier Universitaire de Bordeaux, Centre Hospitalier Universitaire de Lille, Hôpital Claude Huriez, Centre Hospitalier Universitaire de Caen Normandie, CHU Dijon Bourgogne, Hôpital Lyon Sud, Hôpital Pontchaillou, Centre Hospitalier Universitaire de Rennes, Centre Hospitalier Régional et Universitaire de Nancy, Institut universitaire du cancer de Toulouse Oncopole

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4389221077

Cites:

Cited by: 13

Related to: 10